

**PROGRAM
and
ABSTRACTS**



International
Conference
on Malignant Lymphoma
Current Status and Prospects
September 2-5, 1981

Lugano, Switzerland

**PROGRAM
and
ABSTRACTS**



International
Conference
on Malignant Lymphoma
Current Status and Prospects
September 2-5, 1981
Lugano, Switzerland

Chairman:
V. DeVita (Bethesda)

Advisory Board:
C. Berard (Memphis),
S. Rosenberg (Stanford)

Organizing Committee:
G. Bonadonna (Milan),
F. Cavalli (Bellinzona),
M. Rozenzweig (Brussels)

INVITED PARTICIPANTS

Banfi, Alberto	National Cancer Institute of Milan, Italy
Bloomfield, Clara D.	University of Minnesota, Minneapolis, Minnesota, USA
Berard, Costan W.	Division of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
Bonadonna, Gianni	National Cancer Institute of Milan, Italy
Brunner, Kurt W.	Institute for Medical Oncology, University Hospital, Inselspital, Bern, Switzerland
Crowther, Derek	Department of Medical Oncology, University of Manchester, Manchester, England
DeVita, Vincent T.	Director, National Cancer Institute, Bethesda, Maryland, USA
Fisher, Richard I.	National Cancer Institute, Bethesda, Maryland, USA
Fossati, Franca	National Cancer Institute of Milan, Italy
Frei, Emil, III	Director, Sidney Farber Cancer Center, Boston, Massachusetts, USA
Fuks, Zvi	Chairman Department of Radiation and Clinical Oncology, Hadassah University Hospital, Jerusalem, Israel
Gasparini, Marco	National Cancer Institute of Milan, Italy
Glatstein, Eli	National Cancer Institute, Bethesda, Maryland, USA
Hansen, Herbert J.	Memorial Sloan-Kettering Cancer Center, New York, USA
Jaffe, Elaine S.	National Cancer Institute, Bethesda, Maryland, USA
Jenkin, Richard D.	The Ontario Cancer Foundation, Toronto, Ontario, Canada
Jones, Stephen E.	The University of Arizona, Tucson, Arizona, USA
Kaplan, Henry S.	Stanford University Medical Center, Stanford, California, USA

INVITED PARTICIPANTS CONTINUED

Lister, Thomas A.	Department of Medical Oncology, St. Bartholomew's Hospital, London, England
Martz, Georg	Division of Oncology, University Hospital, Zürich, Switzerland
Mathé, Georges	Director, Institute of Cancerology, Villejuif, France
McElwain, T.J.	The Royal Marsden Hospital, London, England
Murphy, Sharon B.	St. Jude Children's Research Hospital, Memphis, Tennessee, USA
Nissen, Nis I.	The Finsen Institute, Copenhagen, Denmark
Obrecht, Paul	Division of Oncology, University Hospital, Basilea, Switzerland
Peckham, M.J.	The Royal Marsden Hospital, London, England
Rappaport, Henry	City of Hope National Medical Center, Duarte, California, USA
Rilke, Franco	National Cancer Institute of Milan, Italy
Rosenberg, Saul A.	Stanford University Medical Center, Stanford, California, USA
Rozenzweig, Marcel	Institute Jules Bordet, Brussels, Belgium
Salem, Philip A.	American University of Beirut Hospital, Beirut, Lebanon
Schmidt, Carl G.	Westdeutsches Tumorzentrum, Essen, West-Germany
Silvestrini, Rosella	National Cancer Institute of Milan, Italy
Tubiana, M.	Institut Gustave-Roussy, Villejuif, France
Ullmann, John E.	The University of Chicago, Chicago, Illinois, USA
Wagner, Hanspeter	Children University Hospital, Bern
Young, Robert C.	National Cancer Institute, Bethesda, Maryland, USA

CONFERENCE SCHEDULE

Wednesday, September 2, 1981
7:30 p.m. - 9:45 p.m.

BIOLOGY AND THERAPEUTIC APPROACHES

Chairman: S. Rosenberg

Time	Abstract	Title, Authors
7:30 p.m.		WELCOME AND ANNOUNCEMENTS. F. Cavalli
7:45 p.m.	1	THE MALIGNANT LYMPHOMAS AS A HUMAN MODEL FOR THE STUDY OF NEOPLASIAS. <u>V. DeVita</u> . Bethesda, USA
8:15 p.m.	2	ADVANCES IN BASIC BIOLOGY RELEVANT TO A BETTER UNDERSTANDING OF HUMAN LYMPHOMAS. <u>H. Kaplan</u> . Stanford, USA
8:45 p.m.	3	EVOLUTION OF CLASSIFICATION OF MALIGNANT LYMPHOMAS. <u>C. Berard</u> . Memphis, USA
9:15 p.m.	4	THE EVOLUTION IN THE TREATMENT STRATEGY OF MALIGNANT LYMPHOMAS. <u>G. Bonadonna</u> . Milan, Italy

Thursday, September 3, 1981
8:00 a.m. - 5:45 p.m.

HODGKIN'S DISEASE - SESSION 1

Chairman: H. Kaplan

8:00 a.m.	5	T-CELL INHIBITOR IN THE SERA OF UNTREATED PATIENTS WITH HODGKIN'S DISEASE. M.M. Bieber and <u>H. Kaplan</u> . Stanford, USA
8:20 a.m.	6	LONG TERM EFFECTS OF TOTAL LYMPHOID IRRADIATION ON THE IMMUNE SYSTEM AND ITS USE AS AN EXPERIMENTAL MODE OF IMMUNOSUPPRESSIVE THERAPY. <u>Z. Fuks</u> and S. Slavin. Jerusalem, Israel
8:40 a.m.	7	IMMUNOLOGIC STUDIES IN HODGKIN'S DISEASE PRIOR TO THERAPY AND AFTER PROLONGED REMISSION. R. Fisher, Ch. Vanhaelen, R. Young and V. DeVita. <u>Bethesda</u> , USA
9:00 a.m.	8	CHARACTERISTICS OF HODGKIN-DERIVED CELL-LINES (L 428, L 439, L 538, L 540). <u>V. Diehl</u> , H.H. Kirchner, M. Schaadt, H. Stein and Ch. Fonatsch. Hannover, West-Germany

Thursday, September 3, 1981
8:00 a.m. - 5:45 p.m. (continued)

- 9:15 a.m. 9 PROGNOSTIC FACTORS AND SUBGROUPS IN HODGKIN'S DISEASE. S. Rosenberg. Stanford, USA
- 9:35 a.m. 10 SEVERE PRURITUS: A "B" SYMPTOM IN HODGKIN'S DISEASE. P. Gobbi, G. Attardo Parrinello, G. Lattanzio, S.C. Rizzo, E. Ascari. Pavia, Italy
- 9:50 a.m. COFFEE BREAK

HODGKIN'S DISEASE - SESSION 2

Chairman: H.-P. Wagner

- 10:10 a.m. 11 AN ANALYSIS OF 528 SCANS USING ABDOMINAL COMPUTED TOMOGRAPHY (CT) IN PATIENTS WITH LYMPHOMA. D. Crowther, G. Blackledge, H. Mamtora, J.J.K. Best and I. Isherwood. Manchester, England
- 10:30 a.m. 12 UPDATE ON STAGING IN HODGKIN'S DISEASE (HD). J. Ullmann, S. Neely, H. Golomb, D. Sweet, E. Lester. Chicago, USA
- 10:50 a.m. 13 LOW DOSE RADIATION AND MOPP CHEMOTHERAPY FOR PEDIATRIC HODGKIN'S DISEASE. H. Kaplan and S.S. Donaldson. Stanford, USA
- 11:05 a.m. 14 CONSERVATIVE MANAGEMENT OF CHILDHOOD HODGKIN'S DISEASE - CHEMOTHERAPY OF LOW TOXICITY, LIMITED RADIOTHERAPY AND NO LAPAROTOMY. R. Nogueira Costa, T. McElwain and A. Barrett. Sutton, England
- 11:20 a.m. 15 HODGKIN'S DISEASE IN CHILDREN. RESULTS IN CLINICALLY STAGED CHILDREN TREATED WITH MOPP AND MODERATE DOSE EXTENDED FIELD RADIATION (EF RT). R. Jenkin, H. Chan, M. Freedman, M. Greenberg, P. McCture, F. Saunders and M. Sonley. Toronto, Canada
- 11:30 a.m. 16 HODGKIN'S DISEASE IN CHILDREN: STAGING AND TREATMENT OF 102 CASES. F. Fossati, R. Musumeci, R. Doci, R. Giardini, C. Gianni, R. Kenda. Milan, Italy
- 11:50 a.m. 17 THE GERMAN COOPERATIVE STUDY FOR THE TREATMENT OF HODGKIN'S DISEASE IN CHILDREN AND ADOLESCENTS: DESIGN AND PRELIMINARY RESULTS. H. Breu, G. Schellong, E.-W. Schwarze, M. Wannemacher. Münster, Kiel, Freiburg, West-Germany
- 12:00 noon LUNCH

Thursday, September 3, 1981
8:00 a.m. - 5:45 p.m. (continued)

HODGKIN'S DISEASE - SESSION 3

Chairman: M. Peckham

- 1:30 p.m. 18 PRESENT STATUS OF PRIMARY CHEMOTHERAPY OF HODGKIN'S DISEASE (HD). V. DeVita. Bethesda, USA
- 2:00 p.m. 19 LONG TERM RESULTS OF RADIOTHERAPY. M. Peckham. Sutton, England
- 2:20 p.m. 20 CLINICAL TRIALS IN HODGKIN'S DISEASE (CS I + II) CARRIED OUT BY THE E.O.R.T.C. RADIOTHERAPY-CHEMOTHERAPY GROUP. M. Tubiana, M. Hayat, M. Henry-Amar. Villejuif, France
- 2:35 p.m. 21 CHEMOTHERAPY-RADIOTHERAPY IN STAGES IB, IIn A, IIB, III HODGKIN'S DISEASE. POSSIBILITY OF CHEMOTHERAPY REDUCTION: RESULTS OF 3 VERSUS 6 COURSES OF M.O.P.P. F. Teillet, Ch. Bayle, B. Asselain, Ph. Lelièvre, Ch. Ferme, M. Boiron, J. Bernard. Colombes, France
- 2:50 p.m. 22 MOPP CHEMOTHERAPY-SELECTIVE NODAL IRRADIATION (RT) IN HODGKIN'S DISEASE (HD)-CLINICAL STAGES (CS) IA-IIIIB. J.-M. Andrieu, C. Bayle, F. Teillet, J. Bernard. Paris, France
- 3:10 p.m. 23 EFFECTIVENESS OF NITROSOUREA (CCNU) CONTAINING 4-DRUG PROGRAMS FOR RADIATION THERAPY FAILURES IN ADVANCED HODGKIN'S DISEASE. M. Cooper, T.F. Pajak, A.S. Glicksman, A.J. Gottlieb, C.D. Bloomfield, N.I. Nissen, C.L. Spurr. Winston-Salem, USA, for CALGB
- 3:25 p.m. 24 INFLUENCE OF MOPP DOSES AND TIMING ON TREATMENT OUTCOME IN ADVANCED HODGKIN'S DISEASE (HD). P. Carde, F.R. MacKintosh, S.A. Rosenberg. Stanford, USA
- 3:40 p.m. COFFEE BREAK

HODGKIN'S DISEASE - SESSION 4

Chairman: K. Brunner

- 4:00 p.m. 25 SECOND MALIGNANCIES IN PATIENTS TREATED FOR HODGKIN'S DISEASE. R. Young, E.J. Glatstein, D.L. Longo, R.I. Fisher and V.T. DeVita. Bethesda, USA

Thursday, September 3, 1981
8:00 a.m. - 5:45 p.m. (continued)

- 4:15 p.m. 26 STERILITY AFTER TREATMENT FOR HODGKIN'S DISEASE.
T. Lister, J. Waxman, P.F.M. Wrigley, R.M.
Chapman, S.B. Sutcliffe, G.M. Besser, L.H. Rees
and J.S. Malpas. London, England
- 4:30 p.m. 27 FERTILITY, PREGNANCY AND PROGENY IN PATIENTS TREATED
FOR HODGKIN'S DISEASE. P. Konitz, P.H. Wiernik,
J. Aisner, C. Rulenz. Baltimore, USA
- 4:45 p.m. PANEL DISCUSSION: CONTROVERSIAL ISSUES IN THE
PRESENT MANAGEMENT OF HODGKIN'S DISEASE.
Moderator: V. DeVita. Participants: Banfi
(Milan), Bonadonna (Milan), Brunner (Bern),
Nissen (Copenhagen), Peckham (London), Rosenberg
(Stanford), Tubiana (Paris)
- 5:45 p.m. ADJOURN

Friday, September 4, 1981
8:00 a.m. - 6:00 p.m.

8:00 a.m. - 10:00 a.m. POSTER SESSION (Room B)

NON HODGKIN'S LYMPHOMAS - SESSION 1

Chairman: G. Mathe

- 10:00 a.m. 28 IMPORTANCE OF BIOLOGIC MARKERS IN NON-HODGKIN'S
LYMPHOMAS (NHL) FROM THE POINT OF VIEW OF THE
PATHOLOGIST. E. Jaffe and J. Cossman. Bethesda,
USA
- 10:20 a.m. 29 IMPORTANCE OF BIOLOGIC MARKERS IN NON-HODGKIN'S
LYMPHOMAS (NHL) FROM THE POINT OF VIEW OF THE
CLINICIAN. C. Bloomfield. Minneapolis, USA
- 10:40 a.m. 30 KINETIC AND PLOIDY CHARACTERISTICS AND THEIR
CLINICAL RELEVANCE IN NON-HODGKIN'S LYMPHOMAS.
R. Silvestrini, A. Costa, G. Del Bino. Milan,
Italy
- 10:55 a.m. 31 CYTOKINETIC STUDIES IN THE NON-HODGKIN'S LYMPHOMAS.
H. Hansen, D. Filippa, M. Andreeff, J. Valauri,
B. Clarkson. New York, USA
- 11:10 a.m. 32 ORAL PRESENTATION OF MALIGNANT LYMPHOMAS. F. Rilke.
Milan, Italy
- 11:25 a.m. 33 NON-HODGKIN'S LYMPHOMA OF WALDEYER'S RING. N. Masaki,
H. Ikeda and Y. Shigematsu. Osaka, Japan

Friday, September 4, 1981
8:00 a.m. - 6:00 p.m. (continued)

- 11:40 a.m. 34 PRIMARY MALIGNANT LYMPHOMA OF WALDEYER'S RING:
CLINICAL ANALYSIS OF 145 CASES. W. Tang,
L. Yu and Y.Zhang. Shanghai, China
- 11:55 a.m. 35 IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE -
A NEW AND A DISTINCT FORM OF MALIGNANT LYMPHOMA.
P. Salem, V. Nassar, Ch. Allam, S. Alami, A. Salem,
K. Jabboury, L. Hashimi and M. Khalyl. Beirut,
Lebanon
- 12:10 a.m. LUNCH

NON HODGKIN'S LYMPHOMAS - SESSION 2

Chairman: C. Schmidt

- 1:45 p.m. 36 LONGITUDINAL STUDIES OF PERIPHERAL BLOOD LYMPHO-
CYTE (PBL)-FUNCTIONS IN NON-HODGKIN'S LYMPHOMAS
(NHL). Ch. Lindemalm, B. Johansson, H. Mellstedt.
Stockholm, Sweden
- 2:00 p.m. 37 IMPLICATIONS OF STAGING AND RESTAGING OF PATIENTS
WITH LYMPHOMA. S. Jones and G.E. Goodman. Tucson,
USA
- 2:15 p.m. 38 NEWER COMBINATION CHEMOTHERAPIES IN NON-HODGKIN'S
LYMPHOMA (NHL). J. Ultmann and D.L. Sweet.
Chicago, USA
- 2:40 p.m. 39 CONSERVATIVE MANAGEMENT OF FOLLICULAR LYMPHOMA.
T. Lister and C. Gallagher. London, England
- 2:55 p.m. 40 MANAGEMENT WITH CHEMOTHERAPY ALONE OF CLINICAL
STAGE I-II LYMPHOMAS OF AGGRESSIVE HISTOLOGICAL
TYPE. F. Cabanillas, L.T. Campos and G.P. Bodey.
Houston, USA
- 3:10 p.m. 41 "AGGRESSIVE" VERSUS "MODERATE" CHEMOTHERAPY VERSUS
CHEMOIMMUNOTHERAPY FOR NON-HODGKIN'S LYMPHOMA
(NHL). S. Jones. Tucson, USA
- 3:20 p.m. 42 PRIMARY CHEMOTHERAPY FOR LOCALIZED DIFFUSE LYMPHOMA.
S. Jones and T.P. Miller. Tucson, USA
- 3:30 p.m. COFFEE BREAK

Friday, September 4, 1981
8:00 a.m. - 6:00 p.m. (continued)

NON HODGKIN'S LYMPHOMAS - SESSION 3 (Room A)

Chairman: P. Obrecht

- 3:45 p.m. 43 ROLE OF RADIATION THERAPY IN THE TREATMENT OF NON-HODGKIN'S LYMPHOMAS. E. Glatstein. Bethesda, USA
- 4:05 p.m. 44 CLINICAL TRIAL USING RADIOTHERAPY AND CHEMOTHERAPY IN NON-HODGKIN'S LYMPHOMA. E.O.R.T.C. RADIO-CHEMOTHERAPY GROUP. R. Somers. Amsterdam, Netherlands
- 4:20 p.m. 45 COMBINED MODALITY TREATMENT OF LYMPHOCYTIC AND HISTIOCYTIC LYMPHOMAS - A CALGB STUDY. H.W. Grünwald, A.S. Glicksman, N.I. Nissen, A.J. Gottlieb and T.F. Pajak. New York, Providence, Syracuse, Scarsdale (USA), Copenhagen (Denmark)
- 4:35 p.m. 46 AFRICAN AND AMERICAN BURKITT'S LYMPHOMA HAVE DIFFERENT CELLULAR ORIGINS: STUDIES WITH CELL LINES AND A SPECIFIC HETEROANTISERUM. I. Magrath, D. Benjamin, R. Parsons, H. Todd-Kulikowski, C. Janus. Bethesda, USA
- 4:50 p.m. 47 PRETREATMENT STRATIFICATION OF CHILDHOOD NON-HODGKIN'S LYMPHOMA (NHL), ACCORDING TO PRIMARY SITE, CLINICAL STAGE, AND IMMUNOPATHOLOGIC SUBTYPE: CURRENT RESULTS OF COMBINED MODALITY PROTOCOLS. S. Murphy, H.O. Hustu, G. Rivera, W.P. Bowman, G.V. Dahl. Memphis, USA
- 5:15 p.m. 48 HISTOLOGY SPECIFIC TREATMENT OF CHILDHOOD NON-HODGKIN'S LYMPHOMA (NHL): RESULTS OF A RANDOMIZED CLINICAL TRIAL. J. Anderson, D. Jenkin, R. Chilcote, P. Coccia, P. Exelby, J. Kersey, J. Kushner, A. Meadows, S. Seigel, J. Wilson, S. Leikin and D. Hammond. Boston, USA
- 5:30 p.m. 49 THE MILAN EXPERIENCE IN THE TREATMENT OF NON HODGKIN LYMPHOMA (NHL) IN CHILDREN. M. Gasparini, F. Lombardi. Milan, Italy
- 5:40 p.m. 50 PROGNOSTIC FACTORS AND TREATMENT OF CNS LYMPHOMA IN ADULTS. R. Young, R.I. Fisher, D.L. Longo and V.T. DeVita. Bethesda, USA
- 6:00 p.m. ADJOURN

Friday, September 4, 1981
8:00 a.m. - 6:00 p.m. (continued)

NON HODGKIN'S LYMPHOMAS - SESSION 4 (Room B)

Chairman: H. Rappaport

- 3:45 p.m. 51 J-CHAIN AS A MARKER OF B NON-HODGKIN MALIGNANT LYMPHOMAS. S. Pileri, L. Serra, M. Populizio and G. Martinelli. Bologna, Italy
- 4:00 p.m. 52 USE OF A B-CELL SPECIFIC MONOCLONAL ANTIBODY AND CONVENTIONAL IMMUNOLOGIC MARKERS FOR TYPING OF MALIGNANT NHL. C. Christen, H.K. Forster, F.G. Gudat, J.P. Obrecht. Basilea, Switzerland
- 4:15 p.m. 53 CLINICOPATHOLOGICAL STUDY OF 22 PATIENTS WITH B-IMMUNOBLASTIC SARCOMAS (B-IBS). D. Bron, B. Van den Heule, M. Rozencweig, H. Bondue, B. Vanderlinden and P. Strijckmans. Brussels, Belgium
- 4:30 p.m. 54 RESULTS OF NON HODGKIN'S LYMPHOMAS TREATMENT ACCORDING TO THE MIXED W.H.O. HISTOCYTOLOGIC AND IMMUNE CATEGORISATION. G. Mathe, J.L. Misset, M. Delgado, B. Caillou, D. Machover, P. Ribaud, C. Jasmin, M. Musset, G. Lemaigre and G. Santelli. Villejuif, France
- 4:45 p.m. 55 PROGNOSTIC RELEVANCE OF THE KIEL CLASSIFICATION OF NON-HODGKIN LYMPHOMAS. G. Brittinger et al, Kiel Lymphoma Study Group. Essen, West-Germany
- 5:00 p.m. 56 THE INTERNATIONAL FORMULATION OF THE PATHOLOGIC CLASSIFICATION OF NON HODGKIN'S LYMPHOMAS. C. Berard. Memphis, USA
- 5:30 p.m. PANEL DISCUSSION CONCERNING PATHOLOGIC CLASSIFICATION OF NHL, including drs. Berard, Rappaport, Rilke
- 6:00 p.m. ADJOURN

Saturday, September 5, 1981
9:00 a.m. - 12:00 noon

NON HODGKIN'S LYMPHOMAS - SESSION 5
Chairman: G. Martz

- 9:00 a.m. 57 LYMPHOBLASTIC LYMPHOMA AND OTHER CHILDHOOD LYMPHOMAS. H. Weinstein, R. Cassidy and E. Frei III. Boston, USA
- 9:20 a.m. 58 THERAPY OF DIFFUSE HISTIOCYTIC (DH) AND UNDIFFERENTIATED (DU) LYMPHOMA WITH HIGH DOSE METHOTREXATE AND LEUCOVORIN FACTOR RESCUE (MTX/LF), BLEOMYCIN (B), ADRIAMYCIN (A), CYCLOPHOSPHAMIDE (C), ONCOVIN (O) AND DECADRON (D) (M-BACOD). A. Skarin, D. Rosenthal, G. Canellos, D. Case, J. McIntyre, G. Pinkus, W. Moloney and E. Frei. Boston, USA
- 9:35 a.m. 59 THE EPIPODOPHYLLOTOXIN VP-16-213 AS AN EFFECTIVE AGENT IN THE TREATMENT OF PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA. P. Jacobs, H.S. King and D. Dent. Cape Town, South Africa
- 9:50 a.m. 60 A RANDOMIZED TRIAL OF HIGH-DOSE CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE WITH OR WITHOUT ADRIAMYCIN (CVP vs CAVP) IN ADVANCED NON-HODGKIN'S LYMPHOMAS (NHL). J.F. Bishop, P.H. Wiernik, R.S. Kaplan, M.N. Wesley, M.P. Barcos and J.C. Sutherland. Baltimore, USA
- 10:05 a.m. 61 NEW DRUGS IN MALIGNANT LYMPHOMAS. M. Rozenzweig, D. Bron, D.D. Von Hoff and F.M. Muggia. Brussels (Belgium), San Antonio, New York (USA)
- 10:30 - 11:30 a.m. PANEL DISCUSSION: PERSPECTIVES OF IMPROVEMENT IN THE TREATMENT OF NHL. Moderator: E. Frei. Participants: Bonadonna (Milan), Bloomfield (Minneapolis), DeVita (Bethesda), Kaplan (Stanford), Glatstein (Bethesda), Nissen (Copenhagen)
- 11:30 a.m. SUMMARY AND CONCLUDING REMARKS. S. Rosenberg. Stanford, USA
- 12:00 noon ADJOURN

ELDISINE[®]

VINDESINE SULFATE, LILLY

The first semisynthetic vinca-alkaloid
with new antitumor potential shows less neurological
disturbances than vincristin.

ELDISINE

has been used for the treatment of various malignancies,
e.g.

acute leucemias
blastcrisis of chronic myeloic leucemia
malignant lymphomas



Eli Lilly and Company
Indianapolis, Indiana 46285

